Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

190.97 +1.98 (+1.05%)
Streaming Delayed Price Updated: 2:59 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
57 58 Next >
News headline image
10 Worst Performing Large-Caps Last 12 Months ↗
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Large-Cap Stocks In Trouble - Saturday, Dec. 21 ↗
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Topics Stocks / Equities
News headline image
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory? ↗
Super Micro faces potential delisting from Nasdaq 100 Index due to underperformance and auditing scandal. Uncertainty surrounds its future. 
Via Benzinga
News headline image
Assessing Biogen: Insights From 19 Financial Analysts ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Biogen Through Analyst Insights ↗
 
Via Benzinga
News headline image
Evaluating Biogen: Insights From 17 Financial Analysts ↗
 
Via Benzinga
News headline image
Biogen Analysts Slash Their Forecasts After Q3 Results ↗
 
Via Benzinga
News headline image
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown ↗
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties. 
Via Benzinga
News headline image
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over ↗
Via The Motley Fool
News headline image
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside ↗
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
Via Benzinga
News headline image
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum ↗
The biotech giant also raised full-year EPS guidance. 
Via Investor's Business Daily
News headline image
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 ↗
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges. 
Via Benzinga
News headline image
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
From Biogen Inc.
Via GlobeNewswire
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
Biogen (BIIB) Q3 2024 Earnings Call Transcript ↗
BIIB earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook ↗
Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance. 
Via Benzinga
News headline image
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
From Biogen Inc.
Via GlobeNewswire
News headline image
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
Robin Kramer, Chief Accounting Officer, to Succeed Him 
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.